Scientists identify new possibility for untreatable blood cancer

Published: Comments:
Community Health & Wellness Science & Research

This is an archived copy of an article. It is online for informational purposes only.
Social:   

Scientists have discovered a new biomarker that could help to unlock the medical mystery behind an untreatable blood cancer that affects mostly older Australians.

QIMR Berghofer Medical Research Institute’s Immunology in Cancer and Infection senior scientist Professor Mark Smyth and clinician researcher Dr Kyohei Nakamura worked with colleagues in France to make the discovery about multiple myeloma.

Multiple myeloma grows in the bone marrow and affects around 1800 Australians every year. The average age of diagnosis is 70 years. The study found a particular molecule called IL-18 supressed the immune system to help create a bone marrow environment where cancer was more likely to grow.

The study analysed the impact of IL-18 on 152 patients with multiple myeloma and found strong evidence that high levels of the molecule were associated with poorer survival.

Professor Smyth said IL-18 was responsible for promoting the immune suppressive function of a particular kind of white blood cell (granulocyte) in the bone marrow.

He said the resulting suppression hindered another kind of immune cell, known as a T cell, from doing its job of finding and destroying cancer cells.

“IL-18 has traditionally been recognised as a growth factor for immune cells because it was thought to promote the activity of the white blood or ‘natural killer’ cells that protect us from infection and cancer,” he said.

“We’ve turned that thinking on its head with our discovery that IL-18 is actually a pro-tumour factor, which causes virtually the opposite effect.

“IL-18 is critical in the progression of multiple myeloma by enabling one part of the immune system to suppress another.”

Professor Smyth said bone marrow IL-18 levels were a potential biomarker for predicting a person’s disease prognosis as well as a potential target for new multiple myeloma treatments.

“Our research shows IL-18 could be an independent prognostic factor, which is very significant,” he said.

“Practically speaking, the higher a person’s IL-18 levels in the bone marrow, the greater the likelihood their immune system is suppressed. That means their prognosis is not as good.”

Dr Nakamura said the findings could one day influence the way patients were treated for multiple myeloma.

“If a person’s prognosis is not as good because they have higher levels of IL-18 in the bone marrow, a doctor might choose to treat the patient more aggressively,” he said.

Dr Nakamura said the discovery was vital to building a better understanding of what caused inflammation in the bone marrow that lead to the development of multiple myeloma.

“Multiple myeloma creates a really inflammatory microenvironment inside the bone marrow,” he said.

“We want to understand the molecular processes underpinning that inflammation.

“This will help us to determine whether this biology is unique to the bone marrow and multiple myeloma, or whether it is also present in other cancers.”

Dr Nakamura said there was even potential to one day work with pharmaceutical partners interested in targeting IL-18 with a unique antibody or small molecule inhibitors.

He said a test for IL-18 in the bone marrow of patients would need to be performed at the point of diagnosis by taking a fluid sample from inside the bones.

The QIMR Berghofer-led research involved multiple collaborators from across the globe and within Australia.

The work was supported by the National Health and Medical Research Council of Australia, Cure Cancer Australia and Cancer Australia through the Cancer Australia Priority-driven Collaborative Cancer Research Scheme.

It was published in Cancer Cell today.

 
QIMR Berghofer Medical Research Institute :
PO Royal Brisbane Hospital, Brisbane, QLD, 4029, Brisbane
07 3845 3752
QIMR Berghofer Medical Research Institute
Showing 9 recent articles for this business
Queensland scientists create functioning human muscle in a dish 10 December 2018 | QIMR Berghofer researchers have created functioning miniature human skeletal muscle – a move that will accelerate research into muscle disease and treatments. More information...
Discovery holds promise for a new oesophageal cancer screening test 04 December 2018 | One of Australia’s most deadly cancers could in future be detected earlier, and with a simple blood test, thanks to research from QIMR Berghofer Medical Research Institute. More information...
QIMR Berghofer helps map the genetic makeup of disease-spreading mosquito 22 November 2018 | QIMR Berghofer scientists have helped map the most complete genetic picture of the potentially deadly Aedes aegypti mosquito. More information...
Clinical trial finds new immunotherapy improves MS symptoms 20 November 2018 | A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has found that it improved symptoms and quality of life for the majority of patients. More information...
Born with a taste for coffee or tea 15 November 2018 | If you have a taste for coffee and want to drink a lot of it, you were probably born that way. More information...
World's largest genetic study of cannabis use identifies 35 genes 28 August 2018 | An international team of researchers has conducted the biggest ever study into genetic predisposition for cannabis use and identified 35 genes that influence whether people are likely to ever use the drug. More information...
Hope for transplant patients after world-first Queensland immunotherapy trial 06 July 2018 | Organ transplant patients who face a lifetime of medication to ward off viral infection – or the potentially deadly threat of drug-resistant infection – may have new hope following a world-first clinical trial... More information...
Major study uncovers new breast cancer genes and opens the door for more discoveries 19 June 2018 | An international team of researchers has used a new scientific method to discover at least 12 new genes that influence the risk of developing breast cancer. More information...
Cancer a hit to the heart and the back pocket 11 June 2018 | One quarter of Queenslanders diagnosed with cancer will pay upfront doctors’ fees of more than $20,000 in the first two years, according to a new study shining a light on out-of-pocket costs for survivors. More information...



Social:   
comments powered by Disqus

All articles submitted by third parties or written by My Sunshine Coast come under our Disclaimer / Terms of Service